Philogen Completes Early Trial of New Prostate Cancer Imaging Agent: What Investors Should Watch

Philogen SpA (DE:78Q) announced an update on their ongoing clinical study.

Philogen’s Study on New Prostate Cancer Imaging Agent Reaches Key Milestone

Philogen S.p.A. has completed a phase I trial titled “A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer.” The main goal was to check if this new imaging agent is safe and how it behaves in the body of men with prostate cancer, including those with rising PSA after treatment. For investors, this is an early but important step in building a new diagnostic tool that could support better detection and monitoring in a large and growing cancer segment.

The study tested a single-dose imaging drug called 68Ga-OncoACP3. It is given by a one-time intravenous injection and is designed to help doctors see prostate cancer more clearly on scans. If it proves safe and effective, it may compete with or complement existing prostate cancer imaging agents and could support future targeted therapies.

The trial used an interventional design, which means patients received the new agent as part of the study. It was non-randomized and open-label, so all participants and doctors knew they were getting 68Ga-OncoACP3. Patients were placed in two parallel groups to study the drug in slightly different clinical settings. The main goal was diagnostic, focused on safety and how the drug spreads and clears from the body, not on treatment effect.

The study began after initial submission on 17 February 2025, marking the formal launch of clinical work. The trial has now reached “Completed” status, showing that planned patient dosing and imaging are finished. While primary and final completion dates are not specified in the extract, the last update on 5 January 2026 signals that recent internal review and data cleaning are underway. No results have yet been posted, which means the key readout and any follow-on communication are still ahead.

For Philogen’s stock (DE:78Q), the completion of this phase I trial reduces early-stage development risk around 68Ga-OncoACP3 and moves the asset closer to value-defining data. If upcoming results show favorable safety and clear imaging performance, the news could support a stronger pipeline story and improved sentiment, especially given growing demand for prostate cancer diagnostics. Investors will compare progress with other imaging and radiopharma players active in prostate cancer, where larger firms already market PSMA-based tracers. Positive data might open the door to partnerships or licensing deals, while weak results could dampen confidence and weigh on the share price.

The study is now marked as completed and recently updated, with more detailed information and future result postings available on the ClinicalTrials portal.

To learn more about DE:78Q’s potential, visit the Philogen SpA drug pipeline page.